Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 10/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 10/20 | 0.46 |
| ▸ | RXRA | P19793 | 6/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16455390 | 0.91 | NR1H2 (0.44) | NR1H2NR1H3RXRALMNAALDH1A1 | |
| SCHEMBL16455255 | 0.91 | NR1H2 (0.48) | NR1H2NR1H3RXRALMNANOTUM | |
| SCHEMBL16455637 | 0.90 | NR1H2 (0.46) | NR1H2NR1H3RXRALMNAALDH1A1 | |
| SCHEMBL15242902 | 0.89 | NR1H2 (0.43) | NR1H2NR1H3RXRALMNANOTUM | |
| SCHEMBL16455383 | 0.89 | RXRA (0.53) | NR1H2NR1H3RXRALMNAPTGS1 | |
| SCHEMBL16455395 | 0.87 | NR1H2 (0.47) | NR1H2NR1H3RXRAPTGS1PTGS2 | |
| SCHEMBL16455239 | 0.86 | RXRA (0.43) | NR1H2NR1H3RXRALMNAPTGS1 | |
| SCHEMBL16455582 | 0.85 | NR1H2 (0.50) | NR1H2NR1H3RXRALMNAPTGS1 | |
| SCHEMBL16455652 | 0.83 | NR1H2 (0.48) | NR1H2NR1H3RXRALMNAALDH1A1 | |
| SCHEMBL16455594 | 0.83 | NR1H2 (0.56) | NR1H2NR1H3RXRALMNAPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210101895-A1 | LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS | RALEXAR THERAPEUTICS, INC. | 2021-04-08 | — | — | US | disclosed |
| EP-3441390-A1 | LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS | Ralexar Therapeutics, Inc. (US) | 2019-02-13 | — | — | EP | disclosed |
| US-20170334897-A1 | Liver X Receptor (LXR) Modulators For The Treatment Of Dermal Diseases, Disorders And Conditions | ALEXAR THERAPEUTICS, INC. | 2017-11-23 | — | — | US | disclosed |
| US-9637481-B2 | Liver X receptor (LXR) modulators for the treatment of dermal diseases, disorders and conditions | RALEXAR THERAPEUTICS, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-20150152094-A1 | LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS | RALEXAR THERAPEUTICS, INC. | 2015-06-04 | — | — | US | disclosed |
| US-8987318-B2 | Liver X receptor (LXR) modulators for the treatment of dermal diseases, disorders and conditions | ALEXAR THERAPEUTICS, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20150045399-A1 | Liver X Receptor (LXR) Modulators For The Treatment Of Dermal Diseases, Disorders And Conditions | ALEXAR THERAPEUTICS, INC. (US) | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045399-A1 | Liver X Receptor (LXR) Modulators For The Treatment Of Dermal Diseases, Disorders And Conditions | NR1H2, NR1H3, RXRA | NR1H2 1/4885NR1H3 2/4885RXRA 3/4885 |
| US-20170334897-A1 | Liver X Receptor (LXR) Modulators For The Treatment Of Dermal Diseases, Disorders And Conditions | NR1H2, NR1H3, RXRA | NR1H2 1/4885NR1H3 2/4885RXRA 3/4885 |
| US-20210101895-A1 | LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS | NR1H2, NR1H3, RXRG | NR1H2 1/4885NR1H3 2/4885RXRA 4/4885 |
| US-20150152094-A1 | LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS | NR1H2, NR1H3, RXRA | NR1H2 1/4885NR1H3 2/4885RXRA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.